带有纳米-spanlastic felodipine配方的粘粘性冷解晶片:开发和表征
Ananda Kumar Chettupalli1, Sarad Pawar Naik Bukke2, Malakapogu Ravindra Babu3
1School of Pharmaceutical Technology, Department of Pharmaceutical Technology, Medical studies, Adamas University, Barbaria, West Bengal, 700126, India. ananda.chettupalli@galgotiasuniversity.edu.in.
Scientific reports
|November 7, 2025
概括
这项研究在口腔晶片中开发了含费洛迪平的纳米晶片,以改善高血压治疗. 这种新型配方通过非侵入性输送途径显著提高了药物的生物可用性和治疗疗效.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 纳米技术 纳米技术
背景情况:
- 费洛迪平 (FDP) 的口服生物可用性较差 (大约 15%) 由于水溶性较低和广泛的第一通代谢.
- 高血压和胸痛是需要有效治疗策略的条件.
- 提高FDP的溶解性和透性对于改善治疗结果至关重要.
研究的目的:
- 开发和评估含有felodipine装载的纳米塑料的冷化口腔晶片.
- 为了提高FDP的溶解性,透性和治疗疗效.
- 研究一种非侵入性输送系统,以改善高血压管理.
主要方法:
- 用felodipine加载的纳米塑料 (FDP-SL) 使用2^3的因数设计进行了准备.
- 配方经过物理化学表征,包括粒子大小,PDI,泽塔潜力和捕获效率.
- 进行了体外透性,体外透性和体内透性研究,并对心脏组织保护进行了他的病理学评估.
主要成果:
- 纳米塑料表现出高捕获效率 (95.38%) 和改进的可变性.
- 与药物悬浮相比,ex vivo研究显示流量增加了4.72倍.
- 在体内研究表明,血压控制显著改善.
- 口腔晶片表现出增强的粘粘和药物释放.
结论:
- 将FDP封装在基于Tween 80的塑料中,并通过粘粘性口腔晶片输送,可以显著提高生物可用性.
- 这种非侵入性方法为改善高血压和胸痛管理提供了一个有希望的策略.
- 开发的纳米-spanlastics口腔晶圆系统代表了传统口服FDP配方的可行替代方案.
相关概念视频
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
386
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
386
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
141
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
141
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.6K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.6K
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
186
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
186
01:14Drug Dissolution: Requirements and Profile Comparison
223
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
223